1. OC-0203: Eliminating tumour hypoxia to improve the impact of immunotherapy. (November 2020) Authors: Marcus, D.; Van der Wiel, A.; Biemans, R.; Lieuwes, N.; Heyerick, A.; Smaill, J.; Patterson, A.; Theys, J.; Yaromina, A.; Lambin, P.; Dubois, L. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OC-0562: Exploiting tumor DNA repair status and hypoxia with CP-506, a novel hypoxia-activated prodrug. (November 2020) Authors: Van der Wiel, A.; Marcus, D.; Niemans, R.; Yaromina, A.; Theys, J.; Mowday, A.; Ashoorzadeh, A.; Anderson, R.; Bull, M.; Abbattista, M.; Heyerick, A.; Guise, C.; Smaill, J.; Patterson, A.; Dubois, L.; Lambin, P. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S313 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SP-0136: Off target effects with hypoxia activated prodrugs: lessons learned from PR-104A. (November 2020) Authors: Mowday, A.; Dubois, L.; Smaill, J.; Patterson, A.; Lambin, P.; Theys, J. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S67 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗